GlobeNewswire by notified

ERYTECH Provides Regulatory Update

Share

ERYTECH Provides Regulatory Update


  • ERYTECH to stop further plans to pursue a BLA submission seeking an approvalfor Graspa® in hypersensitive ALL
  • Evaluation of strategic partnering options ongoing


Cambridge, MA (U.S.) and Lyon (France),August 24, 2022ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, todayprovided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug Administration (FDA).

We are obviously disappointed to stop the process of seeking approval for Graspa in ALL after all the work done and clinical promiseobserved in this indication,said Gil Beyen, Chief Executive Officer of ERYTECH.In multiple clinical trials, Graspa showed promising results for patients, and we were encouraged by the dialogue with the FDA and the Fast Track designation that we received for this indication last year. However, the changing competitive landscape, combined with new FDA’s requests for additional clinical data that would require significant additional resources on our part, led to the difficult decision to stop the development of Graspa in ALL. We are now focusing our resources on our most promising preclinical programs, while pursuing strategic partnering options to maximize value for our shareholders and employees.

Following positive results of a Phase 2 trial, sponsored by the Nordic Organization for Paediatric Haematology and Oncology (NOPHO), presented at the 2020 American Society of Hematology annual meeting, ERYTECH has been in discussions with the FDA for the approval of Graspa to treat ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.

A meeting to discuss the submission of a Biologics License Application (BLA) took place in June 2021, after which the Company confirmed its intention to submit a BLA, subject to the submission of additional requested information to the FDA and agreement on an Initial Pediatric Study Plan (iPSP).

The Company recently received feedback from the FDA on its iPSP, submitted in July 2022. After thorough evaluation of this feedback, which included a new request for additional data, and taking into account the changing competitive landscape in the treatment of hypersensitive ALL, the Company has determined that it is in the best interests of the Company and its shareholders to no longer seek approval for Graspa in ALL and to focus its resources on its preclinical programs and strategic partnering activities.

Following the sale of its production facility in Princeton, New Jersey, for $44.5 million in April 2022, the Company appointed a specialized advisor to evaluate strategic options to leverage its ERYCAPS® platform with complementary assets and/or a broader corporate transaction. Multiple options are under review, and the Company expects to give further updates on these strategic initiatives in the fourth quarter of this year.


About ERYTECH

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States through a long-term supply agreement with Catalent, operating from ERYTECH’s former GMP facility in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.erytech.com

CONTACTS

ERYTECH
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations


+33 4 78 74 44 38
investors@erytech.com


+33 1 44 71 94 94
erytech@newcap.eu


Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding ERYTECH’s business and regulatory strategy and its evaluation of potential strategic transactions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the failure to achieve certain regulatory and commercial milestones; (2) the inability to maintain the listing of ERYTECH’s shares on the Nasdaq Global Select market and the Euronext regulated market; (3) changes in applicable laws or regulations; (4) the possibility that ERYTECH may be adversely affected by other economic, business and/or competitive factors; (5) the inability to agree to terms on a long-term supply agreement with Catalent; and (6) other risks and uncertainties indicated from time to time in ERYTECH’s regulatory filings. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2021 Universal Registration Document (Document d’EnregistrementUniversel) filed with the AMF on April 27, 2022 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 28, 2022 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Boyden Appoints Janne Jakola Partner in Finland3.10.2022 04:00:00 CEST | Press release

Prominent business leader and CEO of Matkahuolto joins Boyden, bringing digital transformation, change leadership and business turnaround expertise to clients worldwide Helsinki, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to welcome prominent business leader Janne Jakola as Partner in Finland effective 1st October 2022. “We at Boyden Finland are delighted to bring such vast technology business and digital services leadership experience to the firm,” commented Erkki Panula, Chairman of Boyden in Finland, and member of the global technology, healthcare & life sciences and fintech practices. “Janne has extensive experience in leading companies and businesses with novel digital services platforms and customer experience, not only in Finland, but in an international context.” Jakola will contribute to Boyden both locally and internationally with C-suite and board assignments as a senior

EMGA completes EUR 9.4M capital raise for Kashf Foundation with financing from BIO3.10.2022 02:00:00 CEST | Press release

LONDON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- The EURO 9.4 million funding facility for Kashf Foundation was originated, structured, and negotiated by Emerging Markets Global Advisory LLP (EMGA), the emerging market investment bank. Speaking on the transaction, Mr Shahzad Iqbal, CFO of Kashf Foundation said, “Kashf Foundation is registered as a Non-Banking Micro Finance Company regulated by the Securities and Exchange Commission of Pakistan. Set up in 1996 as the first specialized microfinance institution of Pakistan it began its operations as a Grameen replicator and since then, Kashf has successfully carved out a distinct and unique niche for itself in the microfinance sector in Pakistan by offering a suite of innovative and transformative products and services to low-income households especially for women. It has a current outreach of over 600,00+ female borrowers across its 360+ branches with a GLP of USD 90+ million.” “Just to share that it has always been a pleasure working with EMGA

FRO - 2022 Annual General Meeting30.9.2022 22:30:00 CEST | Press release

Frontline Ltd. (the “Company”) advises that the 2022 Annual General Meeting of the Shareholders of the Company was held on September 30, 2022 at 08:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2021 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorised to fill such vacancies as and when it deems fit. To re-elect John Fredriksen as a Director of the Company. To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect Ole B. Hjertaker as a Director of the Company. To re-elect Steen Jakobsen as a Director of the Company. To re-appoint PricewaterhouseCoopers AS of Oslo,

GOGL – 2022 AGM Results Notification30.9.2022 22:30:00 CEST | Press release

Golden Ocean Group Limited (the “Company”) advises that the 2022 Annual General Meeting of the Shareholders of the Company was held on September 30, 2022 at 08:30 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2021 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorized to fill such vacancies as and when it deems fit. To re-elect John Fredriksen as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Bjørn Tore Larsen as a Director of the Company. To re-elect Ben Mills as a Director of the Company. To re-appoint PricewaterhouseCoopers AS

Wolters Kluwer acquires Open Access publisher30.9.2022 20:45:00 CEST | Press release

Wolters Kluwer acquires Open Accesspublisher; Expands Breadth of Lippincott Journal Portfolio Waltham, MA, September 30, 2022 – Wolters Kluwer Health announced today that it has signed and completed an agreement to acquire IJS Publishing Group (IJSPG), a UK-based provider of peer-reviewed medical journals supporting scientists and authors. The IJSPG portfolio consists of 10 journal titles, including the International Journal of Surgery (IJS), IJS Case Reports (IJSCR), and Annals of Medicine and Surgery (AMS). IJSPG will become part of Health Learning, Research & Practice (LRP), which offers the Ovid®medical researchsolution, publishes over 300 medical journals and hundreds of medical and nursing books, and produces digital nursing solutions for education and practice. The acquisition expands the breadth and depth of the Lippincott journal portfolio with high impact factor, surgery-related research and strengthens its Open Access position with several well-established journals accessibl